Milken Institute | Research | Publications |
Fixes in Financing: Financial Innovations for Translational Research
|
Fixes in Financing: Financial Innovations for Translational Research
March
2012
|
The biopharmaceutical industry needs novel approaches to early-stage drug development that better manage risk, lower capital cost and improve research effectiveness, create diverse portfolios, leverage risk-tolerant capital, and access new capital sources.
With these issues in mind, the Milken Institute and FasterCures hosted a Financial Innovations Lab on July 19, 2011, in New York City. The Lab was convened to address an industry-wide gap in funding for drug development - the so-called valley of death.
This report, "Fixes in Financing: Financial Innovations for Translational Research," highlights various approaches for managing and financing translational research that were discussed during the Lab, including:
Virtual product/portfolio development companies
Venture philanthropy and government-backed investment vehicles
Innovative investor tax incentives
Securitized research-based obligations
|
|
|
 |
 |
 |
|
|
|
 |
 |
2 ways to subscribe to
the Milken Institute Review |
|
Download the app for
iPhone, iPad and Kindle
Buy new digital editions of our quarterly economics journal for $1.99, purchase back issues for 99 cents or get a year's subscription for $5.99. Access links to related video and other content. |
 |
 |
Order a 1-year subscription
Receive hard copies for $59, a small price to pay for our edgy, accessible and expert take on the latest in economics.
 |
|
| |
|
